AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04455581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1209
Description: SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
Study NCT02903888 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel (Jaydess, Skyla, BAY86-5028)
Description: Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
Study NCT01351441 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Beer's Criteria Assessment
Description: The patient's drug therapy will be reviewed for Beer's criteria medications and possible alternatives will be addressed by the pharmacist if deemed appropriate.
Study NCT01351441 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Literacy Assessment
Description: Patients will be given a Health Literacy Assessment on day 0 and day 365 using the Realm-SF.
Study NCT04451330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifarotene cream
Description: Trifarotene 50 mcg/g cream applied topically once daily on face for 12 weeks.
Study NCT04451330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate
Description: Doxycycline hyclate delayed release 120 mg tablets was administered orally for 12 weeks.
Study NCT04451330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trifarotene Vehicle
Description: Trifarotene 50 mcg/g vehicle cream was applied topically once daily on face for 12 weeks.
Study NCT04451330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycycline Placebo
Description: Doxycycline hyclate delayed release 120 mg placebo tablets was administered orally for 12 weeks.
Study NCT04905667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB221
Description: 6 mg/kg, single dose, intravenous infusion, 90-100 min
Study NCT04905667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: 6 mg/kg, single dose, intravenous infusion, 90-100 min
Study NCT01307930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)
Study NCT03075163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Specifically trained personnel will apply pressure on the wrists bilaterally at the P6 point for up to 3 minutes. The P6 point is located three fingerbreadths from the wrist crease on the volar surface of the arm between the palmaris longus and flexor carpi radialis.~In the event of failure in the acupressure group, further treatments will be identical to the control group. Since Ondansetron is the standard Post Anesthetic Care Unit treatment, it will be first line rescue therapy except in the case that the patient has received 8mg in the past 6 hours. If needed, further antiemetic pharmacologic treatments may include, but are not limited to, phenergan, metoclopramide, haloperidol, diphenhydramine or propofol at the clinical discretion of the patient's anesthesiology care team.
Study NCT03075163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron is a medication that belongs to the drug class known as antiemetic and selective 5-HT3 receptor antagonist. Ondansetron is prescribed for the treatment of nausea and vomiting due to cancer chemotherapy and also used to prevent and treat nausea and vomiting after surgery.
Study NCT02065453 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: disposable device (Ligasure, Covidien)
Description: One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien). . We will randomize the side for each energy source used on each side for every case. The number of sides performed by the attending surgeon will equal that of the less experienced resident surgeon.
Study NCT02065453 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Reusable device
Description: One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
Study NCT00844233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irinotecan Bead
Description: Irinotecan eluting bead
Study NCT05014477 — intervention group
Intervention type: PROCEDURE
Intervention: Removal or leaving of LAA occluders
Description: After LAA device embolization there are different approaches to dealing with the occluder dislocation. The aim is to find out which way leads to the best outcomes.
Study NCT03120832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PAN-301-1
Study NCT00556426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bard Recovery G2 Filter System
Description: Retrieval of previously placed RECOVERY G2 IVC filter
Study NCT03986255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: The participant is placed lateral or sitting position. Fluoroscopy may be used to guide sampling. Full aseptic technique is used throughout.~The skin is prepared with either 2% chlorhexidine/70% alcohol or iodine. 1% lidocaine is used for skin local anesthesia an entry point is identified, this may be done using fluoroscopy. This will be at the lowest intervertebral foramina interspace to minimize the risk of spinal cord injury. A small amount to head up tilt will be allowed to optimize CSF flow.~Sampling is done using a needle through needle technique. An epidural needle is used to identify the epidural space using loss of resistance to saline technique. A spinal needle (26G) is then passed through the epidural needle into the subarachnoid space. Correct entry is noted once CSF is noted in the needle hub and 5 ml taken. This sample is then sent off for analysis.~Once the CSF is sampled, the needle is removed and pressure applied to the skin entry point.
Study NCT02881034 — intervention group
Intervention type: DRUG
Intervention: Triple therapy
Study NCT00944034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ with routine vaccinations
Description: rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
Study NCT00944034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ with routine vaccinations
Description: rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
Study NCT00944034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Description: rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
Study NCT00944034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Description: rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
Study NCT00944034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ with routine vaccinations
Description: rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 months of age
Study NCT00944034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ with routine vaccinations
Description: rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 18 months of age
Study NCT04250662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS with guided imagery
Description: The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have 20 minutes of stimulation with 25 minutes of guided imagery.
Study NCT04250662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS alone (no guided imagery)
Description: The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Active tDCS arm alone without guided imagery, will have 20 minutes of tDCS stimulation without guided imagery.
Study NCT01447667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance elastography
Description: Magnetic resonance elastography before RFA and Liver biopsy of 2 HCC tissue and 2 non tumor liver parenchyma tissue
Study NCT00944034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: two doses of rMenB+OMV NZ
Description: two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age.
Study NCT00944034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ with routine vaccinations
Description: rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
Study NCT00944034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: two doses of rMenB+OMV NZ
Description: two catch-up doses of rMenB+OMV NZ at 18 and 20 months of age
Study NCT00944034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ
Description: rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
Study NCT00944034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: two doses of rMenB+OMV NZ
Description: two catch-up doses of rMenB+OMV NZ at 24 and 26 months of age
Study NCT00944034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMenB+OMV NZ with routine vaccinations
Description: rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 (Group 3a), 18 (Group 3b) or 24 (Group 3c) months of age
Study NCT00384241 — intervention group
Intervention type: BEHAVIORAL
Intervention: Induced Stress
Description: Participation in an active coping task by playing a video game against another participant.
Study NCT00384241 — intervention group
Intervention type: PROCEDURE
Intervention: Buccal Swab
Description: One Buccal swab collected from each parent
Study NCT01072292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: CBT-I is a six week program designed to improve sleep quality in people with COPD.
Study NCT01072292 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I
Description: CBT-I is a six week program designed to improve sleep quality in people with COPD.
Study NCT01868984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel solution treatment of each lesion encountered will be attempted until the 20 mg Paclitaxel dose limit is met. The volume administered will depend on the diameter and length of the venous outflow segment.
Study NCT01868984 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard Therapy
Description: Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
Study NCT01868984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
Study NCT00510276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine hydrochloride
Description: 20-50 mg, twice a day per by mouth for 12 weeks, followed by up to an additional 12 weeks
Study NCT00510276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice a day, by mouth for 12 weeks
Study NCT02427048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback with Peer Comparison
Description: Email detailing adherence to CAP and SS CPG for every month since start of study. Physicians will be provided individualized feedback and given patient identifiers for each patient that received non-adherent care.
Study NCT02250209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is given by intravenous infusion at 440mg on day 0every 3 weeks. Number of cycles: 14\~16 cycles.
Study NCT02250209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 800\~1000 mg/m² is given orally twice a day for 14 days followed by a 1-week rest.~Number of cycles: 8 cycles.
Study NCT02250209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is given by intravenous infusion at 130 mg/m2 on day 1 every 3 weeks.~Number of cycles: 8 cycles.
Study NCT04250662 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS with guided imagery
Description: The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus sham tDCS arm will have 30 seconds of tDCS stimulation with 25 minutes of guided imagery.
Study NCT02123290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265 ymg
Description: Dose of DSM265 to be determined based on the results of the second cohort
Study NCT02538484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Aromatase inhibitor
Study NCT02538484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Omega-3 free fatty acid
Study NCT01961544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: 1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
Study NCT02327091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alfacalcidol
Description: One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
Study NCT00701714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX575 recombinant human erythropoietin alfa
Description: Solution for injection (s.c.)
Study NCT00701714 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ERYPO
Description: Solution for injection (s.c.)
Study NCT04250662 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS alone (no guided imagery)
Description: The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. Sham tDCS alone arm will have 30 seconds of tDCS stimulation without guided imagery.
Study NCT03416283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Monitoring
Description: Remote BP monitoring and medication adherence
Study NCT03416283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Monitoring + Social Support
Description: Remote BP monitoring and medication adherence with enhanced support from a support partner (facilitated cheerleading)
Study NCT01363687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic postconditioning
Description: Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the upper limb free of arteriovenous fistula and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
Study NCT03825913 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Training sessions will include a split routine based on the day of the week.~* Session 1 (e.g. Tuesday) - aerobic exercise (20-30 min) followed by resistance training (10 stacked-weight machines: leg press, leg extension, leg curl, chest press, latissimus pull, shoulder press, seated row, triceps press, biceps curl, and chest fly) for 1-2 sets of 8-12 repetitions.~* Session 2 (e.g. Thursday) - resistance bands and body weight exercises (4-6 exercises, 2 sets of 10-20 repetitions) followed by core exercises (2-3 sets of 10-20 repetitions) and aerobic training (20-30 min) at the end.~The starting training intensities will be at 50-55% of each individual's estimated maximum heart rate for aerobic exercise and one-repetition maximum for resistance training (assessed at baseline only for chest press and leg press). We plan a 5% monthly increase in the intensity to reach 65-70%% of one's maximum efforts by the end of the intervention.
Study NCT03825913 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wellness Intervention
Description: In our setting, ten lectures in nutrition, exercise and various complementary and integrative medicine topics (e.g. acupuncture and Chinese medicine, mindfulness, quality sleep, etc.) were implemented among non-cancer individuals and modified based on their feedback.
Study NCT01876576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear liquids
Description: Clear liquids
Study NCT01876576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low residue breakfast and lunch
Description: Low residue
Study NCT02139553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhythmic rehabilitation
Description: Stroke patients have 12 rehabilitation sessions on a planar rehabilitation robot, Reaplan, focussed on rhythmic arm movements.
Study NCT03635359 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: analysis of cell-free DNA in maternal plasma
Study NCT00467220 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: calorie restriction
Description: Subjects in the calorie restriction arm and the alternate day fasting arm will be asked to follow a menu plan, for three months, that includes some level of calorie restriction.
Study NCT01582672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard treatment for Renal Cell Carcinoma
Study NCT01582672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-003
Description: Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.
Study NCT01389102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol transdermal one 90 μL spray
Description: Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
Study NCT01389102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol transdermal spray, two 90 μL sprays
Description: Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
Study NCT01389102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol transdermal three 90 μL sprays
Description: Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
Study NCT01389102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal two 90 μL sprays
Description: Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
Study NCT01389102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal three 90 μL sprays
Description: Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
Study NCT01389102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal one 90 μL spray
Description: Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator